Allosteric modulators targeting cannabinoid cb1 and cb2 receptors: implications for drug discovery
Abstract
Allosteric modulators of cannabinoid receptors hold great therapeutic potential, as they do not possess intrinsic efficacy, but instead enhance or diminish the receptor's response of orthosteric ligands allowing for the tempering of cannabinoid receptor signaling without the desensitization, tolerance and dependence. Allosteric modulators of cannabinoid receptors have numerous advantages over the orthosteric ligands such as higher receptor type selectivity, probe dependence and biased signaling, so they have a great potential to separate the therapeutic benefits from side effects own of orthosteric ligands. This review aims to give an overview of the CB1 and CB2 receptor allosteric modulators highlighting the structure–activity relationship and pharmacological profile of each classes, and their future promise.
Papers of special note have been highlighted as: • of interest; •• of considerable interest
References
- 1. . New approaches and challenges to targeting the endocannabinoid system. Nat. Rev. Drug Discov. 17(9), 623–639 (2018).
- 2. . More surprises lying ahead. The endocannabinoids keep us guessing. Neuropharmacology 76(Pt B), 228–234 (2014).
- 3. . Cannabinoid receptor-related orphan G protein-coupled receptors. Adv. Pharmacol. 80, 223–247 (2017).
- 4. . Endocannabinoid system: a multi-facet therapeutic target. Curr. Clin. Pharmacol. 11(2), 110–117 (2016).
- 5. . Targeting cannabinoid CB2 receptors in the central nervous system. medicinal chemistry approaches with focus on neurodegenerative disorders. Front. Neurosci. 10, 406 (2016).
- 6. . Minireview: from the bench, toward the clinic: therapeutic opportunities for cannabinoid receptor modulation. Mol. Endocrinol. 29(6), 801–813 (2015).
- 7. . Cannabinoid receptors in the central nervous system: their signaling and roles in disease. Front. Cell. Neurosci. 10, 1–10 (2017).
- 8. . Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities. Philos. Trans. R. Soc. B: Biol. Sci. 367(1607), 3353–3363 (2012).
- 9. . CB1 and CB2 receptor pharmacology. Adv Pharmacol. 80, 169–206 (2017).
- 10. . Synthetic cannabinoid receptor agonists and antagonists: implication in CNS disorders. Recent Pat. CNS Drug Discov. 10(2), 142–156 (2016).
- 11. . Re-visiting the endocannabinoid system and its therapeutic potential in obesity and associated diseases. Curr Diab. Rep. 17(10), 99 (2017).
- 12. The endocannabinoid system in mental disorders: evidence from human brain studies. Biochem. Pharmacol. 157, 97–107 (2018).
- 13. . Cannabinoids in depressive disorders. Life Sci. 213, 18–24 (2018).
- 14. . Current evidence of cannabinoid-based analgesia obtained in preclinical and human experimental settings. Eur. J. Pain 22, 471–484 (2018).
- 15. The endogenous cannabinoid system: a budding source of targets for treating inflammatory and neuropathic pain. Neuropsychopharmacology 43, 52–79 (2018).
- 16. . The endocannabinoid system and its therapeutic exploitation in multiple sclerosis: Clues for other neuroinflammatory diseases. Prog. Neurobiol. 160, 82–100 (2018).
- 17. . Traditional uses of cannabinoids and new perspectives in the treatment of multiple sclerosis. Medicines (Basel) 5(3), 91 (2018).
- 18. . Role of the endocannabinoid system in drug addiction. Biochem. Pharmacol. 157, 108–121 (2018).
- 19. Cannabinoid CB1 receptor neutral antagonist AM4113 inhibits heroin self-administration without depressive side effects in rats. Acta Pharmacol. Sin. 40(3), 365–373 (2019).
- 20. . The pharmacologic and clinical effects of medical cannabis. Pharmacotherapy 33, 195–209 (2013).
- 21. . Cannabinoid receptor 2 signaling in neurodegenerative disorders: from pathogenesis to a promising therapeutic target. Front. Neurosci. 11, 30 (2017).
- 22. . Cannabinoids as modulators of cell death: clinical applications and future directions. Rev. Physiol. Biochem. Pharmacol. 173, 63–88 (2017).
- 23. . Cannabinoid-induced apoptosis in immune cells as a pathway to immunosuppression. Immunobiol. 215, 598–605 (2010).
- 24. . Emerging paradigms in GPCR allostery: omplications for drug discovery. Nat. Rev. Drug Discov. 12(8), 630–644 (2013). • Discusses the potential advantages of allosteric ligands and highlights opportunities that arise from these advantages.
- 25. . Opportunities and challenges in the discovery of allosteric modulators of GPCRs. Methods Mol. Biol. 1705, 297–319 (2018).
- 26. Allosteric modulation of a cannabinoid G protein-coupled receptor: binding site elucidation and relationship to G protein signaling. J. Biol. Chem. 289(9), 5828–5845 (2014). • Describes the binding site of allosteric modulator ORG27569 at CB1 receptors.
- 27. Endogenous vs exogenous allosteric modulators in GPCRs: a dispute for shuttling CB1 among different membrane microenvironments. Sci Rep. 5, 15453 (2015).
- 28. . In silico mapping of allosteric ligand binding sites in type-1 cannabinoid receptor. Biotechnol. Appl. Biochem. 65(1), 21–28 (2018).
- 29. Modeling, molecular dynamics simulation, and mutation validation for structure of cannabinoid receptor 2 based on known crystal structures of GPCRs. J. Chem. Inf. Model. 54(9), 2483–2499 (2014).
- 30. . Negative allosteric modulators of cannabinoid receptor 2: protein modeling, binding site identification and molecular dynamics simulations in the presence of an orthosteric agonist. J. Biomol. Struct. Dyn. 5, 1–16 (2019).
- 31. . Allosteric modulators of GPCRs: A novel approach for the treatment of CNS disorders. Nat. Rev. Drug Discov. 8(1), 41–45 (2009).
- 32. . Applying structure-based drug design approaches to allosteric modulators of GPCRs. Trends Pharmacol. Sci. 38(9), 837–847 (2017). • Considers the types of allosteric pockets and the mode of modulation as well as the advantages and disadvantages of targeting allosteric pockets respect to the natural orthosteric site.
- 33. . Novel allosteric modulators of G-protein coupled receptors. J. Biol. Chem. 290, 19478–19488 (2015).
- 34. Discovery of positive allosteric modulators and silent allosteric modulators of the μ-opioid receptor. Proc. Natl Acad. Sci. USA. 110, 10830–10835 (2013).
- 35. . The future of type 1 cannabinoid receptor allosteric ligands. Drug Metab. Rev. 50(1), 14–25 (2018).
- 36. . Enhanced endocannabinoid tone as a potential target of pharmacotherapy. Life Sci. 204, 20–45 (2018).
- 37. . Endocannabinoid System and Migraine Pain: An Update. Front. Neurosci. 12, 172 (2018).
- 38. . Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery. Pharmacol. Rev. 62, 265–304 (2010).
- 39. . Biased signalling and allosteric machines: new vistas and challenges for drug discovery. Br. J. Pharmacol. 165(6), 1659–1669 (2012).
- 40. . Biased signalling: from simple switches to allosteric microprocessors. Nat. Rev. Drug Discov. 17(4), 243–260 (2018). •• Presents recent evidences that biased agonists have the potential to increase clinical efficacy while reducing undesirable side effects.
- 41. Allosteric modulation of the cannabinoid CB1 receptor. Mol. Pharmacol. 68(5), 1484–1495 (2005).
- 42. . Allosteric modulator ORG27569 induces CB1 cannabinoid receptor high affinity agonist binding state, receptor internalization, and Gi protein-independent ERK1/2 kinase activation. J. Biol. Chem. 287(50), 12070–12082 (2012).
- 43. CB1 receptor allosteric modulators display both agonist and signaling pathway specifity. Mol. Pharmacol. 83(2), 322–338 (2013).
- 44. . Biased agonism and biased allosteric modulation at the CB1 receptors. Mol. Pharmacol. 88(2), 368–379 (2015).
- 45. . Real-time characterization of cannabinoid receptor 1 (CB1) allosteric modulators reveals novel mechanism of action. Br. J. Pharmacol. 170(4), 893–907 (2013).
- 46. . A key agonist – induced conformational change in the cannabinoid receptor CB1 is blocked by the allosteric ligand Org 27569. J. Biol. Chem. 287(40), 33873–33882 (2012).
- 47. . Structural dynamics and energetics underlying allosteric inactivation of the cannabinoid receptor CB1. Proc Natl Acad Sci USA 112(27), 8469–8479 (2015).
- 48. . Distinct roles of β-arrestin 1 and β-arrestin 2 in ORG27569-induced biased signaling and internalization of the cannabinoid receptor 1 (CB1). J. Biol. Chem. 288(14), 9790–800 (2013).
- 49. . Aiming for allosterism: evaluation of allosteric modulators of CB1 in a neuronal model. Pharmacol. Res. 99, 370–376 (2015).
- 50. In-vivo pharmacological evaluation of the CB1-receptor allosteric modulator Org-27569. Behav. Pharmacol. 25(2), 182–185 (2014).
- 51. . Effects of the cannabinoid CB1 receptor allosteric modulator ORG 27569 on reinstatement of cocaine- and –methamphetamine-seeking behaviour in rats. Drug Alcohol Depend. 143, 251–256 (2014).
- 52. Indole 2-carboxamides as allosteric modulators of the cannabinoid CB1 receptor. J. Med. Chem. 55(11), 5627–5631 (2012).
- 53. Structure–activity relationship study of Indole-2-carboxamides identifies a potent allosteric modulator for the cannabinoid receptor 1 (CB1). J. Med. Chem. 56(20), 7965–7975 (2013).
- 54. Novel Electrophilic and Photoaffinity Covalent Probes for Mapping the Cannabinoid 1 Receptor Allosteric Site(s). J. Med. Chem. 59(1), 44–60 (2016).
- 55. Structure–activity relationships of substituted 1H-indole-2-carboxamides as CB1 receptor allosteric modulators. Bioorg Med Chem. 23(9), 2195–2203 (2015).
- 56. . Allosteric modulators of the CB1 cannabinoid receptor: a structural update review. Cannabis and Cannabinoid Res. 1(1), 196–201 (2016).
- 57. Optimization of chemical functionalities of indole-2-carboxamides to improve allosteric parameters for the cannabinoid receptor 1 (CB1). J. Med. Chem. 57(7), 3040–3052 (2014).
- 58. PSNCBAM‐1, a novel allosteric antagonist at cannabinoid CB1 receptors with hypophagic effects in rats. Br. J. Pharmacol. 152(5), 805–814 (2007).
- 59. The great divide: separation between in vitro and in vivo effects of PSNCBAM-based CB1 receptor allosteric modulators. Neuropharmacology. 125, 365–375 (2017).
- 60. . Effects of the allosteric antagonist 1-(4-Chlorophenyl)-3-[3-(6-pyrrolidin-1-ylpyridin-2-yl)phenyl]urea (PSNCBAM-1) on CB1 receptor modulation in the cerebellum. Mol. Pharmacol. 79(4), 758–767 (2011).
- 61. Novel diarylurea based allosteric modulators of the cannabinoid CB1 receptor: evaluation of importance of 6-pyrrolidinylpyridinyl substitution. J. Med. Chem. 60(17), 7410–7424 (2017).
- 62. Diarylureas as allosteric modulators of the cannabinoid CB1 receptor: structure–activity relationship studies on 1-(4-chlorophenyl)-3-{3-[6-(pyrrolidin-1-yl)pyridin-2-yl]phenyl}urea (PSNCBAM-1). J. Med. Chem. 57(18), 7758–7769 (2014).
- 63. . Pyrimidinyl biphenylureas: identification of new lead compounds as allosteric modulators of the cannabinoid receptor CB1. J. Med. Chem. 60(3), 1089–1104 (2017).
- 64. Novel analogs of PSNCBAM-1 as allosteric modulators of cannabinoid CB1 receptor. Bioorg. Med. Chem. 25(24), 6427–6434 (2017).
- 65. A cannabinoid CB1 receptor-positive allosteric modulator reduces neuropathic pain in the mouse with no psychoactive effects. Neuropsychopharmacology. 40(13), 2948–2959 (2015).
- 66. Enantiomer-specific positive allosteric modulation of CB1 signaling in autaptic hippocampal neurons. Pharmacol. Res. 129, 475–481 (2018).
- 67. Multiple binding sites contribute to the mechanism of the 2-phenylindole mixed orthosteric agonistic and PAM action on the Cannabinoid CB1 receptor. Angew. Chem. Int. Ed. Engl. 57(10), 2580–2585 (2018).
- 68. . CB1 positive allosteric modulation attenuates Δ9-THC withdrawal and NSAID-induced gastric inflammation. Pharmacol. Biochem. Behav. 177, 27–33 (2019).
- 69. Enantiospecific allosteric modulation of cannabinoid 1 receptor. ACS Chem. Neurosci. 8(6), 1188–1203 (2017). •• Reports the first demonstration of enantiomer-selective CB1 receptor positive allosteric modulation.
- 70. . Positive allosteric modulation of cannabinoid receptor type 1 suppresses pathological pain without producing tolerance or dependence. Biol. Psychiatry. 84(10), 722–733 (2018).
- 71. The in vivo effects of the CB1-positive allosteric modulator GAT229 on intraocular pressure in ocular normotensive and hypertensive mice. J. Ocul. Pharmacol. Ther. 33(8), 582 –590 (2017).
- 72. .
WO2013103967 (2017). - 73. .
WO2016029310 , (2018). - 74. Identification of the First synthetic allosteric modulator of the CB2 receptors and evidence of its efficacy for neuropathic pain relief. J. Med. Chem.
doi: 10.1021/acs.jmedchem.8b00368 (2018) (Epub ahead of print). - 75. Polypharmacological profile of 1,2-dihydro-2-oxo-pyridine-3-carboxamides in the endocannabinoid system. Eur. J. Med. Chem. 154, 155–171 (2018).
- 76. Pharmacological identification Of Iqm311 as an allosteric modulator of the cannabinoid CB2 receptor. Presented at: 9th Conference on Cannabinoids in Medicine. Cologne, Germany, 29–30 (2017).
- 77. . Characterization of allosteric modulators of CB2 receptors as novel therapeutics for inflammatory diseases. PhD Thesis, The University of Arkansas for Medical Sciences (2011).
- 78. Pregnenolone can protect the brain from cannabis intoxication. Science 343, 6166 (2014).
- 79. . Pregnenolone does not interfere with the effects of cannabinoids on synaptic transmission in the cerebellum and the nucleus accumbens. Pharmacol. Res. 123, 51–61 (2017).
- 80. Atypical Endocannabinoid signaling initiates a new form of memory-related plasticity at a cortical input to hippocampus. Cerebral Cortex 28, 2253–2266 (2018).
- 81. Pregnenolone blocks cannabinoid-induced acute psychotic-like states in mice. Mol. Psychiatry. 22(11), 1594–1603 (2017).
- 82. Ajulemic acid, a synthetic cannabinoid, increases formation of the endogenous proresolving and anti-inflammatory eicosanoid, lipoxin A4. FASEB Journal. 23(5), 1503–1509 (2009).
- 83. . Aspirin-triggered lipoxin induces CB1-dependent catalepsy in mice. Neurosc.i Lett. 470(1), 33–37 (2010).
- 84. Anti-inflammatory lipoxin A4 is an endogenous allosteric enhancer of CB1 cannabinoid receptor. Proc. Natl Acad. Sci. USA 109(51), 21134–21139 (2012).
- 85. Novel endogenous peptide agonists of cannabinoid receptors. The FASEB Journal. 23(9), 3020–3029 (2009).
doi:10.1096/fj.09-132142 . - 86. . Localization and production of peptide endocannabinoids in the rodent CNS and adrenal medulla. Neuropharmacology 98, 78–89 (2015).
- 87. . Hemopressins and other hemoglobin-derived peptides in mouse brain: comparison between brain, blood, and heart peptidome and regulation in Cpefat/fat mice. J. Neurochem. 113(4), 871–880 (2011).
- 88. Identification and Quantification of a New Family of Peptide Endocannabinoids (Pepcans) Showing Negative Allosteric Modulation at CB1 Receptors. J. Biol. Chem. 287(44), 36944–36967 (2012).
- 89. . Pepcan-12 (RVD-hemopressin) is a CB2 receptor positive allosteric modulator constitutively secreted by adrenals and in liver upon tissue damage. Sci Rep. 7(1), 9560 (2017).
- 90. . The role of nuclear hormone receptors in cannabinoid function. Adv Pharmacol. 80, 291–328 (2017).
- 91. . A potential role for cannabinoid receptors in the therapeutic action of fenofibrate. FASEB J. 29(4), 1446–1455 (2015).
- 92. . Positive allosteric modulation of the human cannabinoid (CB) receptor by RTI-371, a selective inhibitor of the dopamine transporter. Br. J. Pharmacol. 156(7), 1178–1184 (2009).
- 93. 2-isoxazol-3-phenyltropane derivatives of cocaine: molecular and atypical system effects at the dopamine transporter. J. Pharmacol. Exp. Ther. 349(2), 297–309 (2014).
- 94. . Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. Br. J. Pharmacol. 150(5), 613–623 (2007).
- 95. . Cannabidiol is a negative allosteric modulator of the type 1 cannabinoid receptor. Br. J. Pharmacol. 172(20), 4790–4805 (2015).
- 96. Binding and signaling studies disclose a potential allosteric site for cannabidiol in cannabinoid CB2 receptors. Front. Pharmacol. 8), 744 (2017).
- 97. . Allosteric and orthosteric pharmacology of cannabidiol and cannabidiol-dimethylheptyl at the type 1 and type 2 cannabinoid receptors. Br. J. Pharmacol. 176(10), 1455–1469 (2018).
- 98. . Enantiomeric cannabidiol derivatives: synthesis and binding to cannabinoid receptors. Org. Biomol. Chem. 3(6), 1116–1123 (2005).
- 99. . In silico mapping of allosteric ligand binding sites in type-1 cannabinoid receptor. Biotechnol. Appl. Biochem. 65(1), 21–28 (2018). •• Presents in silico docking study of the crystal structure of CB1 receptor on endogenous and natural hydrophobic ligands that act as positive allosteric and negative allosteric modulators.